Triptans for migraine headaches: a review of clinical evidence on safety
CADTH
Record ID 32012000662
English
Authors' recommendations:
While no consistent differences were found between triptans in the rates of overall adverse events (AEs), a small number of studies suggest oral, intranasal and subcutaneous sumatriptan are associated with chest pain and tachycardia. The most common AEs include dizziness, drowsiness, paresthesia, nausea and fatigue. One study suggests that providing a clinical limit of 27 rizatriptan ODT 10 mg/month did not reduce the number of migraine days compared with providing a formulary limit of 9 tablets per month. Regardless of quantity, rizatriptan ODT 10 mg was well tolerated as AEs were similar between groups.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/mar-2012/RC0333%20Triptans%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Analgesics
- Migraine Disorders
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.